Oxylanthanum Carbonate

Unicycive Therapeutics to Resubmit OLC NDA After FDA Type A Meeting

Los Altos, California, October 28, 2025 — Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for kidney disease,...

By cGxPwire Editor
October 28, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Oxylanthanum Carbonate

Unicycive Therapeutics to Resubmit OLC NDA After FDA Type A Meeting